ICU Medical, Inc. logo

ICU Medical, Inc.

ICUI

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$182.84

+$0.31 · +0.17%

Aug 21, 4:00 PM ET

ICUI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

58

Fair Value

Momentum

60

Neutral

Sentiment

68

Bullish

Risk resilience

70

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Vivek Jain
Listed since
Mar 31, 1992
Employees
13,000

Market position

Day range

Current $182.84

52-week range

Current $182.84

Open
$182.15
Previous close
$182.53
Volume
182.32K
0.6× average
Average volume
305.94K
Average daily volume
Market cap
4.57B USD
Beta
0.75
Market reference 1
50-day average
$160.63
+13.82% above average
200-day average
$143.66
+27.27% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.6B USD
P/E (TTM)
152.37×
P/B (TTM)
2.12×
P/S (TTM)
2.12×
EV / EBITDA
14.09×
Earnings yield
0.02%
Free cash flow yield
2.61%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
37.56%
Operating margin
5.04%
Net margin
1.39%
Return on equity
0.03%
Return on assets
0.02%
Return on invested capital
0.69%

Financial health

Debt / equity
0.59×
Current ratio
2.36×
Altman Z-score
2.56
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends42%25%8%-9%Gross margin, FY2021: 37.34%Gross margin, FY2022: 30.60%Gross margin, FY2023: 32.75%Gross margin, FY2024: 34.62%Gross margin, FY2025: 36.76%Operating margin, FY2021: 9.36%Operating margin, FY2022: -1.88%Operating margin, FY2023: 1.01%Operating margin, FY2024: 1.80%Operating margin, FY2025: 4.80%Net margin, FY2021: 7.84%Net margin, FY2022: -3.26%Net margin, FY2023: -1.31%Net margin, FY2024: -4.94%Net margin, FY2025: 0.03%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 37.34%. Gross margin FY2022 30.60%. Gross margin FY2023 32.75%. Gross margin FY2024 34.62%. Gross margin FY2025 36.76%. Operating margin FY2021 9.36%. Operating margin FY2022 -1.88%. Operating margin FY2023 1.01%. Operating margin FY2024 1.80%. Operating margin FY2025 4.80%. Net margin FY2021 7.84%. Net margin FY2022 -3.26%. Net margin FY2023 -1.31%. Net margin FY2024 -4.94%. Net margin FY2025 0.03%.

Income trends

Revenue

2.23B USD-6.38%

Operating income

106.95M USD+148.93%

Net income

732K USD+118.42M USD
Income trends across reported periods2.63B USD1.63B USD632.23M USD−367.66M USDRevenue, FY2021: 1.32B USDRevenue, FY2022: 2.28B USDRevenue, FY2023: 2.26B USDRevenue, FY2024: 2.38B USDRevenue, FY2025: 2.23B USDOperating income, FY2021: 123.25M USDOperating income, FY2022: −42.9M USDOperating income, FY2023: 22.83M USDOperating income, FY2024: 42.96M USDOperating income, FY2025: 106.95M USDNet income, FY2021: 103.14M USDNet income, FY2022: −74.29M USDNet income, FY2023: −29.66M USDNet income, FY2024: −117.69M USDNet income, FY2025: 732K USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.32B USD. Revenue FY2022 2.28B USD. Revenue FY2023 2.26B USD. Revenue FY2024 2.38B USD. Revenue FY2025 2.23B USD. Operating income FY2021 123.25M USD. Operating income FY2022 −42.9M USD. Operating income FY2023 22.83M USD. Operating income FY2024 42.96M USD. Operating income FY2025 106.95M USD. Net income FY2021 103.14M USD. Net income FY2022 −74.29M USD. Net income FY2023 −29.66M USD. Net income FY2024 −117.69M USD. Net income FY2025 732K USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.23B USD2.38B USD2.26B USD2.28B USD1.32B USD
Cost of goods sold1.41B USD1.56B USD1.52B USD1.58B USD824.82M USD
Gross profit819.66M USD824.78M USD739.87M USD697.76M USD491.49M USD
Research and development87.5M USD88.62M USD85.34M USD92.98M USD47.5M USD
Selling, general, and administrative625.21M USD638.76M USD606.69M USD608.35M USD302.58M USD
Operating expenses712.71M USD781.82M USD717.05M USD740.66M USD368.25M USD
Interest income10.31M USD10.79M USD7.51M USD4.43M USD2.84M USD
Interest expense105.38M USD106.54M USD102.73M USD70.81M USD858K USD
Depreciation and amortization217.99M USD2.44M USD228.77M USD235.15M USD99.29M USD
Operating income106.95M USD42.96M USD22.83M USD−42.9M USD123.25M USD
Net income732K USD−117.69M USD−29.66M USD−74.29M USD103.14M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+32.03%
11 comparable reports
Latest EPS result
2.37
Estimate 1.91 · Beat by 24.08%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.462.021.581.14Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 2.11, estimate 1.48, surprise +42.57%, Beat. Q2 2025, reported May 8, 2025: actual 1.72, estimate 1.23, surprise +39.84%, Beat. Q3 2025, reported Aug 7, 2025: actual 2.1, estimate 1.44, surprise +45.83%, Beat. Q4 2025, reported Nov 6, 2025: actual 2.03, estimate 1.43, surprise +41.96%, Beat. Q1 2026, reported Feb 19, 2026: actual 1.91, estimate 1.68, surprise +13.69%, Beat. Q2 2026, reported May 7, 2026: actual 1.97, estimate 1.78, surprise +10.67%, Beat. Q3 2026, reported Aug 6, 2026: actual 2.37, estimate 1.91, surprise +24.08%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 2.13, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates655M598.75M542.51M486.27MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 629.81M USD, estimate 599.1M USD, surprise +5.13%, Beat. Q2 2025, reported May 8, 2025: actual 604.7M USD, estimate 603.7M USD, surprise +0.17%, Beat. Q3 2025, reported Aug 7, 2025: actual 548.87M USD, estimate 511.46M USD, surprise +7.31%, Beat. Q4 2025, reported Nov 6, 2025: actual 536.99M USD, estimate 511.48M USD, surprise +4.99%, Beat. Q1 2026, reported Feb 19, 2026: actual 535.94M USD, estimate 530.58M USD, surprise +1.01%, Beat. Q2 2026, reported May 7, 2026: actual 525.77M USD, estimate 520.65M USD, surprise +0.98%, Beat. Q3 2026, reported Aug 6, 2026: actual 547.88M USD, estimate 533.44M USD, surprise +2.71%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 552.13M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$186.4

1.95% upside
Past 12 months12-month forecastHigh $200Average $186.4Low $163

Rating distribution

12 ratings
Strong buy18%
Buy1083%
Hold18%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions
BTIGmaintainBuy
JefferiesupgradeHoldBuy

ICUI news

Corporate actions

Corporate action history

Stock split

Effective Mar 18, 2002

3:2

Stock split

Effective Apr 1, 1993

3:2

ICUI peers

ETFs holding ICUI

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ICUI

research.disclaimer